Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain

Annals of Neurology

Volumn 64, Issue 3, 2008, Pages 274-283

  Ranoux, Danièle ^a   Attal, Nadine ^b,c,d   Morain, Francoise ^b,c,d   Bouhassira, D ^b,c,d  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b Institut National de la Sante et de la Recherche Médicale U 792

^c HÔPITAL AMBROISE PARÉ   (France)

^d LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

ADULT; AGED; ALLODYNIA; ANALGESIA; ANALGESIC ACTIVITY; ANXIETY; ARTICLE; CHRONIC DISEASE; CHRONIC PAIN; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COLD SENSATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; EUPHORIA; FEMALE; HEAT SENSATION; HUMAN; INJECTION PAIN; INJECTION SITE PAIN; MALE; MECHANICAL ALLODYNIA; MECHANICAL STIMULATION; MONOTHERAPY; NEUROPATHIC PAIN; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PAIN THRESHOLD; PRIORITY JOURNAL; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYMPTOM; SYSTEMIC DISEASE;

ADULT; AGED; ANALGESICS; BOTULINUM TOXIN TYPE A; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERALGESIA; INJECTIONS, INTRADERMAL; MALE; MIDDLE AGED; NEURALGIA; NEUROMUSCULAR AGENTS; NOCICEPTORS; PAIN MEASUREMENT; PAIN THRESHOLD; PERIPHERAL NERVES; PERIPHERAL NERVOUS SYSTEM DISEASES; PLACEBOS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 54849435847     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.21427     Document Type: Article

References (53)

1. Ward AB, Molenaers G, Colosimo C, Berardelli A. Clinical value of botulinum toxin in neurological indications. Eur J Neurol 2006;13(suppl 4):20-26.
2. Brashear A, Gordon MF, Elovic E, et al; Botox Post-Stroke Spasticity Study Group. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002;347:395-400.
3. Heckmann M, Ceballos-Baumann AO, Plewig G; Hyperhidrosis Study Group. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med 2001;344:488-493.
4. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005;26:785-793.
5. Mense S. Neurobiological basis for the use of botulinum toxin in pain therapy. J Neurol 2004;251(suppl 1):I1-I7.
6. Simpson LL. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 2004;44:167-193.
7. Handwerker HO. Nociceptors: neurogenic inflammation. In Cervero F, Jensen TS, eds. Handbook of clinical neurology. Vol 81. Pain. Amsterdam: Elsevier, 2006:23-33.
8. Ishikawa H, Mitsui Y, Yoshitomi T, et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol 2000;44:106-109.
9. Purkiss J, Welch M, Doward S, Foster K. Capsaïcin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol 2000;59:1403-1406.
10. Meunier FA, Colasante C, Faille L, et al. Upregulation of calcitonin gene related peptide at mouse motor nerve terminals poisoned with botulinum type-A toxin. Pflugers Arch 1996;431(suppl 2):R297-R298.
11. Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004;44:35-42.
12. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004;107:125-133.
13. Morenilla-Palao C, Planells-Cases R, Garcia-Sanz N, Ferrer-Montiel A. Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem 2004;279:25665-25672.
14. Luvisetto S, Marinelli S, Lucchetti F, et al. Botulinum neurotoxins and formalin-induced pain: central vs peripheral effects in mice. Brain Res 2006;1082:124-131.
15. Bach-Rojecky L, Relja M, Lackovic Z. Botulinum toxin type A in experimental neuropathic pain. J Neural Transm 2005;112:215-219.
16. Luvisetto S, Marinelli S, Cobianchi S, Pavone F. Anti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain. Neuroscience 2007;145:1-4.
17. Park HJ, Lee Y, Lee J, et al. The effects of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain. Can J Anesth 2006;53:470-477.
18. Zieglgansberger W, Berthele A, Tolle TR. Understanding neuropathic pain. CNS Spectr 2005;10:298-308.
19. Cline MA, Ochoa J, Torebjork HE. Chronic hyperalgesia and skin warming caused by sensitized C nociceptors. Brain 1989;112:621-647.
20. Fields HL, Rowbotham M, Baron R. Postherpetic neuralgia: irritable nociceptors and deafferentation. Neurobiol Dis 1998; 5:209-227.
21. Petersen KL, Fields HL, Brennum J, et al. Capsaicin evoked pain and allodynia in post-herpetic neuralgia. Pain 2000;88:125-133.
22. Hall GC, Carroll D, Parry D, McQuay HJ. Epidemiology and treatment of neuropathic pain: the UK primary care perspective. Pain 2006;122:156-162.
23. Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet 2006;367:1618-1625.
24. Attal N, Haanpaa M, Hansson P, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006;13:1153-1169.
25. Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005;118:289-305.
26. Hempenstall K, Nurmikko TJ, Johnson RW, et al. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med 2005;2:164.
27. Argoff CE. A focused review on the use of botulinum toxins for neuropathic pain. Clin J Pain 2002;18:S177-S181.
28. Freund B, Schwartz M. Subcutaneous BTX-A in the treatment of neuropathic pain: a pilot study. Presented at: 38th Interagency Botulism Research Coordinating Meeting; October 17-19, 2001; Easton, MD.
29. Jabbari B, Maher N, Difazio MP. Botulinum toxin A improved burning pain and allodynia in two patients with spinal cord pathology. Pain Med 2003;4:206-210.
30. Liu HT, Tsai SK, Kao MC, Hu JS. Botulinum toxin A relieved neuropathic pain in a case of post-herpetic neuralgia. Pain Med 2006;7:89-91.
31. Naumann M, Flachenecker P, Brocker EB, et al. Botulinum toxin for palmar hyperhidrosis. Lancet 1997;349:252.
32. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129-138.
33. Wallace MS, Rowbotham MC, Katz NP, et al. A randomized, double-blind, placebo-controlled trial of a glycine antagonist in neuropathic pain. Neurology 2002;59:1694-1700.
34. Attal N, Rouaud J, Brasseur L, et al. Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. Neurology 2004;62:218-225.
35. Ducreux D, Attal N, Parker F, Bouhassira D. Mechanisms of central neuropathic pain: a combined psychophysical and fMRI study in syringomyelia. Brain 2006:129:963-976.
36. Bouhassira D, Attal N, Fermanian J, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain 2004;108:248-257.
37. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-370.
38. Gazerani P, Staahl C, Drewes AM, Arendt-Nielsen L. The effects of botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain 2006;122:315-325.
39. Tugnoli V, Capone JG, Eleopra R, et al. Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin. Pain 2007;130:76-83.
40. Blersch W, Schulte-Mattler WJ, Przywara S, et al. Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study. J Neurol Sci 2002;205:59-63.
41. Krämer HH, Angerer C, Erbguth F, et al. Botulinum toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol 2003;250:188-193.
42. Schulte-Mattler WJ, Opatz O, Blersch W, et al. Botulinum toxin A does not alter capsaicin-induced pain perception in human skin. J Neurol Sci 2007;260:38-42.
43. Sycha T, Samal D, Chizh B, et al. A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model. Anesth Analg 2006;102:509-516.
44. Voller B, Sycha T, Gustorff B, et al. A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A. Neurology 2003;61:940-944.
45. Ranoux D, Gury C, Fondarai J, et al. Respective potencies of Botox and Dysport: a double-blind, randomized, cross-over study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002;72:459-462.
46. Dong M, Yeh F, Tepp WH, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006;312:592-596.
47. Attal N, Bouhassira D. Mechanisms of pain in peripheral neuropathy. Acta Neurol Scand 1999;(suppl 173):12-24.
48. Bouhassira D, Lanteri-Minet M, Attal N, et al. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain (in press).
49. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain 2006;7:281-289.
50. Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 2007;68:1178-1182.
51. Smith BH, Torrance N, Bennett MI, Lee AJ. Health and quality of life associated with chronic pain of predominantly neuropathic origin in the community. Clin J Pain 2007;23:143-149.
52. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007;132:237-251.
53. Vadoud-Seyedi J, Simonart T. Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study. Br J Dermatol 2007;156:986-989.